Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

The pharma industry has spent much of the last year navigating the Trump administration's tariff threats, but with a seismic Supreme Court ruling Friday, the president's emergency import taxes have ...

Novo Nordisk’s board of directors is still going through changes. | The new proposed board members come after an extraordinary general meeting last fall saw a significant change in leadership.

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project ...

After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...

Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply ...

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...

Eli Lilly is partnering on Team USA’s push to help Olympic and Paralympic athletes hurdle the challenges of recovering from ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce ...

In recent months, Johnson & Johnson has massively upped its spending on television advertisements for immunology heavyweight Tremfya, with the brand ...